What this means
This trial gave people ABBV-CLS-7262, rosuvastatin, and digoxin in two parts. It has finished, but no results have been shared yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 18–65
- Where
- 1 site, including Illinois
The science
- Registered title
- A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
- Trial ID
- NCT05763459 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Healthy
- What is tested
- ABBV-CLS-7262
- Sponsor
- Calico Life Sciences LLC
- Ages
- 18 Years to 65 Years
- Dates
- First posted Mar 10, 2023 · updated Jun 26, 2023
Registry summary
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
Sites (1)
- AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States